Coccidioidomycosis.
Coccidioidomycosis is a largely self-limited fungal respiratory illness. However, the infrequent case of progressive or disseminated disease can be devastating. As international travel to and from endemic areas increases, physicians unfamiliar with the disease may be called upon to recognize and treat serious coccidioidal infections. The major risk factors for dissemination are race and immunosuppression. The most common sites of dissemination are the skin, lymph nodes, bone and meninges. Diagnosis is aided by investigation of the patient's clinical history, delayed-type hypersensitivity skin test reaction, serologic testing, and recovery of organisms from infected tissue or secretions for direct examination and culture. Fungicidal agents are not available, fortunately, fungistatic therapy allows many patients to recover. The availability of both intravenous/intrathecal and oral agents now allows more therapeutic flexibility in the treatment of this disease.
Bronnimann
D A
DA
Department of Internal Medicine, University of Arizona College of Medicine, Tucson 85724.
Galgiani
J N
JN
D000666:Amphotericin B / Q000627:therapeutic use; D003045:Coccidioides / Q000302:isolation & purification; D003047:Coccidioidomycosis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D007108:Immune Tolerance; D007654:Ketoconazole / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D012307:Risk Factors
D000666:Amphotericin B; D007654:Ketoconazole